# Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

> **NCT05981118** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Wake Forest University Health Sciences** · enrollment: 40 (estimated)

## Conditions studied

- ICD10 Code L40.9 for Psoriasis

## Interventions

- **DRUG:** Betamethasone dipropionate 0.05%
- **DRUG:** Tapinarof

## Key facts

- **NCT ID:** NCT05981118
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-07-15
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05981118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05981118, "Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05981118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*